Mabwell’s Nectin-4 ADC Shows Promise in TNBC Phase 2 Data
Event summary
- Mabwell will present Phase 2 data on its Nectin-4-targeting ADC, 9MW2821 (Bulumtatug Fuvedotin), for triple-negative breast cancer at ESMO 2026.
- The oral presentation is scheduled for October 26, 2026, during the advanced breast cancer session.
- Prof. Zhang Jian of Fudan University Shanghai Cancer Center will present the results (Abstract No.: 4640RO).
- 9MW2821 targets patients with locally advanced or metastatic TNBC previously treated with Topoisomerase I inhibitor-based ADCs.
The big picture
Mabwell’s presentation at ESMO 2026 underscores the growing focus on ADCs for difficult-to-treat cancers like TNBC. The company is positioning itself as a key player in oncology innovation, competing with established and emerging biopharma firms developing targeted therapies. Success here could validate its fully integrated industry chain strategy and bolster its market position.
What we're watching
- Clinical Efficacy
- How the Phase 2 data on 9MW2821 compares to existing TNBC treatments in terms of safety and efficacy.
- Regulatory Pathway
- Whether Mabwell can leverage these results to accelerate regulatory approvals for 9MW2821.
- Market Positioning
- The pace at which Mabwell can differentiate 9MW2821 in a competitive ADC landscape.